Paper Details

  1. Home
  2. Paper Details

Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life.

Author: BreedJ G, JoostenJ, KragtenJ A, LustermansF A, MooijJ M, Van BortelL M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Nebivolol, a selective beta 1-adrenoceptor antagonist, effectively lowered blood pressure without affecting quality of life perception. It had a favorable safety profile and no evidence of central nervous system side effects.
Paper Details　
Original Abstract of the Article :
Nebivolol is a selective beta 1-adrenoceptor antagonist with a particular hemodynamic profile, suggesting an ancillary vasodilating property. The nature of this ancillary property is still unknown. The present double-blind placebo-controlled multicenter study investigated the effect of 4 and 8 weeks...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/7687708

データ提供：米国国立医学図書館（NLM）

Nebivolol: A Potential Oasis in the Desert of Hypertension

Hypertension, a common medical condition, can have far-reaching consequences for overall health. This study investigates the effectiveness and safety of nebivolol, a beta-blocker with potential vasodilating properties, in managing hypertension. The researchers conducted a double-blind, placebo-controlled multicenter study to evaluate the impact of nebivolol on blood pressure, heart rate, blood parameters, ECG, and quality of life. The study provides valuable insights into the therapeutic potential of nebivolol in managing hypertension and the potential impact on patient well-being.

Nebivolol Shows Promise in Managing Hypertension

The study found that nebivolol demonstrated a significant antihypertensive effect, effectively lowering blood pressure in both supine and standing positions. The researchers also found that nebivolol did not impair quality of life and had a favorable adverse effect profile. This suggests that nebivolol may be a safe and effective treatment option for hypertension, with potential benefits for both physical and mental well-being.

Exploring the Desert of Hypertension Management

This study offers a glimpse into the potential of nebivolol to transform hypertension management. By providing an effective and well-tolerated treatment option, nebivolol may offer individuals a path toward better cardiovascular health and a more fulfilling life. It underscores the importance of personalized treatment approaches and the ongoing search for safe and effective therapies to manage chronic conditions.

Dr. Camel's Conclusion

Nebivolol emerges as a potential oasis in the desert of hypertension management. The study's findings suggest that this medication can provide effective blood pressure control while minimizing adverse effects and preserving quality of life. The research emphasizes the need for individualized care and the continuous pursuit of innovative treatment options to address the complex challenges of hypertension.

Date :
  1. Date Completed 1993-08-20
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

7687708

DOI: Digital Object Identifier

7687708

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.